Alembic Pharmaceuticals has received USFDA approval for Olopatadine Hydrochloride ophthalmic solution, used to treat allergic conjunctivitis.
The approved product is therapeutically equivalent to the reference listed drug product (RLD) Patanol ophthalmic solution, 0.1 per cent, of Novartis Pharmaceuticals Corporation. According to market estimates, Olopatadine Hydrochloride ophthalmic solution has an estimated market size of $61 million for 12 months ending December 2017.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply